Vetsulin (porcine insulin zinc suspension) U-40 Cartridge for VetPen, 10 cartridges of 2.7-mL

The first and only insulin approved by the US Food and Drug Administration for treating both canine and feline diabetes mellitus. Vetsulin (porcine insulin zinc suspension) is produced by Merck Animal Health and is available only by prescription.

if Vetsulin is discontinued or not given as directed, the signs of diabetes will return and life-threatening complications such as ketoacidosis may develop. Therefore, it is important to maintain therapy in a consistent manner and monitor your dog's glucose level correctly.

Contact your veterinarian immediately. An animal with signs of hypoglycemia should be treated immediately. Glucose should be given orally or intravenously as dictated by clinical signs. Insulin should be temporarily withheld and, subsequently, the dosage should be adjusted, if indicated.

Prior to loading vetsulin cartridges, shake the cartridge until a homogeneous, uniformly milky suspension is obtained. Clumps or white particles can form in insulin suspensions: do not use the product if visible clumps or white particles persist after shaking. The detailed instructions for use provided with VetPen should be strictly followed. The injection should be administered subcutaneously, 2 to 5 cm (3/4 to 2 in) from the dorsal midline, varying from behind the scapulae to the mid-lumbar region and alternating sides.

The injection should be administered subcutaneously, 2 to 5 cm (3/4 to 2 in) from the dorsal midline, varying from behind the scapulae to the mid-lumbar region and alternating sides.

VETSULIN CARTRIDGES SHOULD BE USED EXCLUSIVELY WITH VETPEN AND 29G/12 MM PEN NEEDLES. The veterinarian should re-evaluate the cat at appropriate intervals and adjust the dose based on clinical signs, urinalysis results, and glucose curve values until adequate glycemic control has been attained. Further adjustments in dosage may be necessary with changes in the cat’s diet, body weight, or concomitant medication, or if the cat develops concurrent infection, inflammation, neoplasia, or an additional endocrine or other medical disorder.